Blood tests to predict mirabegron response in overactive bladder
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at whether simple blood tests can predict how well women with overactive bladder will respond to a medicine called mirabegron. If you have had symptoms for at least 3 months and your doctor plans to start mirabegron, this study may help tailor your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- You have had overactive bladder symptoms for at least 3 months
- Your doctor has decided to start mirabegron 50 mg as part of your usual care
- You have not had previous overactive bladder treatments other than behavioral therapy (like bladder training)
- You do not have certain health conditions like active infections, chronic inflammatory diseases, cancer, blood disorders, or severe kidney or liver problems
- You are able to understand and sign a consent form and complete a bladder diary
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines, solifenacin and mirabegron, to see which one works better and has fewer side effects for people with overactive bladder. It aims to find the best treatment option to reduce urgency and frequent urination.
This study tests a new treatment (TRG-200 KIT) for overactive bladder (OAB) that is put directly into the bladder through a small tube. It aims to help people who have not gotten enough relief from other treatments.
This study compares different treatments for overactive bladder in women in Taiwan. It aims to find the best approach to help control symptoms like frequent or urgent urination.
This study looks at the bacteria in the bladders of women with overactive bladder who are getting Botox injections. It aims to understand how these bacteria might affect treatment results.
This study tests a new bladder treatment called NT 201 combined with a device called the Vibe System for women with overactive bladder (frequent, urgent need to urinate). The treatment is injected directly into the bladder and may help reduce urgency and leaking.
This study compares vaginal estradiol (a hormone placed in the vagina) versus an oral beta-3 medicine called mirabegron for overactive bladder symptoms. It looks to see which treatment works better and is safer for postmenopausal women.
Hear when a new Overactive Bladder (OAB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.